However, a network meta-analysis reported increased circulating MCP-1 only in patients with hepatic steatosis, but not in NASH compared to controls [144], whereas a recent meta-analysis reported similar circulating MCP-1 between patients with NAFLD and controls [27]. Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.